Product Information Sheet for NR-4143

Monovalent Influenza Subvirion Vaccine, rgA/Vietnam/1203/2004(H5N1)

Catalog No. NR-4143

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

Aventis Pasteur, Inc.

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*
Agent: Influenza A virus
Strain/Isolate: rgA/Vietnam/1203/2004(H5N1)
Comments: Monovalent influenza subvirion vaccine, rgA/Vietnam/1203/2004(H5N1) was deposited at ATCC® in 2006 by Roland A. Levandowski, M.D., Chief, Influenza, SARS and ORVD Section, NIAID, NIH, Bethesda, Maryland. A plasmid rescue system was used to generate the vaccine.[1,2] Briefly, mammalian cells were transfected with plasmids carrying the hemagglutinin (HA) and neuraminidase genes derived from the A/Vietnam/1203/2004(H5N1) strain of influenza virus, while all other plasmid-encoded genes were derived from the A/Puerto Rico/8/1934(H1N1) strain of influenza A virus. The HA gene was modified by replacement of the polybasic cleavage site that is associated with the high pathogenicity of H5N1 influenza A viruses in birds. The rgA/Vietnam/1203/2004 x A/Puerto Rico/8/1934 (H5N1) influenza virus that was generated using these techniques was found to be antigenically identical to the wild-type A/Vietnam/1203/2004(H5N1) virus and was apathogenic in chickens.[1] To prepare the vaccine product, the seed virus was grown to high titer in chicken eggs, collected by centrifugation, and inactivated with formalin. It was then disrupted with Triton X-100, filtered to remove bacteria and further purified. The vaccine has shown safety and immunogenicity in a double-blind, placebo-controlled clinical trial.[1]

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2005 season are now past their expiration dates.

Material Provided:

Each vial contains ~ 0.7 mL of formulated monovalent influenza subvirion vaccine, rgA/Vietnam/1203/2004(H5N1), without preservative.

Packaging/Storage:

NR-4143 was packaged aseptically in glass serum vials. The product is provided on refrigerated bricks and should be stored at 2–8°C immediately upon arrival.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Monovalent Influenza Subvirion Vaccine, rgA/Vietnam/1203/2004(H5N1), NR-4143."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Treanor, J. J., et al. "Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine." N. Engl. J. Med. 354 (2006): 1343–1351. PubMed: 16571878.
2. Neumann, G., et al. "Generation of Influenza A Viruses Entirely from Cloned cDNAs." Proc. Natl. Acad. Sci. U.S.A. 96 (1999): 8804–8806. PubMed: 10430945.

Support Provided by NIAID

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898